Her-2

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer free. This is the biography of Her-2, Herceptin, the drug that provoked dramatic responses in Barbara and other women in the trials that offers promise for hundreds of thousands of women.